- Home
- Media centre
- Press kits
- ASCO press kit
American Society of Clinical Oncology (ASCO) press kit
The information on this page is intended for healthcare and business journalists and analysts/investors.
Press releases
- 1 June 2008 - New data offer insights into the potential role for Tykerb® / Tyverb® (lapatinib) in non-cytotoxic chemotherapy-based treatment regimens
- 31 May 2008 - New data for pazopanib – GSK’s latest investigational anti-cancer agent – shows promise across multiple cancers
- 30 May 2008 - New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma
- 29 May 2008 - GlaxoSmithKline announces new drug application and Phase III results for Rezonic™ / Zunrisa™ (casopitant)
- 20 May 2008 - Elesclomol study shows significant improvement in progression-free survival for chemotherapy-naïve patients with metastatic melanoma
- 16 May 2008 - GSK announces results of first Phase III trial evaluating Tykerb®/Tyverb® (lapatinib) plus Herceptin® (trastuzumab)
Breast cancer
- Tykerb/Tyverb (lapatinib) fact sheet (PDF 36Kb)
- Pazopanib fact sheet (PDF 35Kb)
- Angiogenesis fact sheet (PDF 36Kb)
Melanoma
- Elesclomol fact sheet (PDF 38Kb)
